Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
See, Ray Meng Teo, Yao Neng Teo, Yao Hao Syn, Nicholas L Yip, Alicia Swee Yan Leong, Shariel Wee, Caitlin Fern Cheong, Alex Jia Yang Lee, Chi-Hang Chan, Mark Yan-Yee
See, Ray Meng
Teo, Yao Neng
Teo, Yao Hao
Syn, Nicholas L
Yip, Alicia Swee Yan
Leong, Shariel
Wee, Caitlin Fern
Cheong, Alex Jia Yang
Citations
Altmetric:
Alternative Title
Abstract
INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly utilized in the treatment of diabetes mellitus as well as therapeutic extra-glycemic effects. However, there are still concerns over complications such as amputation events, given the results from the Canagliflozin Cardiovascular Assessment Study (CANVAS) trial. Hence, we conducted a systematic review and meta-analysis of randomized-controlled trials to investigate the effect of SGLT2 inhibitors on amputation events. METHODS: Four electronic databases (PubMed, Embase, Cochrane, and SCOPUS) were searched on November 21, 2020, for articles published from January 1, 2000, up to November 21, 2020, for studies that examined the effect of SGLT2 inhibitors on amputation events. Random-effect pair-wise meta-analysis for hazard ratios and fixed-effect Peto odds ratio meta-analysis were utilized to summarize the studies. RESULTS: A total of 15 randomized-controlled trials were included with a combined cohort of 63,716 patients. We demonstrated that there was no significant difference in amputation events across different types of SGLT2 inhibitors, different baseline populations, and different duration of SGLT2 inhibitor use. DISCUSSION/CONCLUSIONS: In this meta-analysis, SGLT2 inhibitors were not associated with a significant difference in amputation events.
Keywords
Amputations, Sodium-glucose cotransporter 2 inhibitors
Source Title
Pharmacology
Publisher
S. Karger AG
Series/Report No.
Collections
Rights
Date
2021-12-23
DOI
10.1159/000520903
Type
Article